Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 2/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29626722 | 0.77 | NR3C2 (0.44) | TYK2NR3C2MEN1KMT2APOLB | |
| SCHEMBL21200001 | 0.77 | NR3C2 (0.44) | TYK2NR3C2MEN1KMT2APOLB | |
| SCHEMBL514592 | 0.75 | NOS3 (0.48) | PLGPLAUUGT2B7MEN1KMT2A | |
| SCHEMBL19846691 | 0.72 | UHRF1 (0.48) | PLGPLAUUGT2B7MEN1KMT2A | |
| SCHEMBL17198732 | 0.72 | UHRF1 (0.48) | PLGPLAUUGT2B7MEN1KMT2A | |
| SCHEMBL21079077 | 0.71 | FDPS (0.37) | NR3C2FDPS | |
| SCHEMBL21200276 | 0.71 | PLG (0.41) | PLGPLAUUGT2B7MEN1KMT2A | |
| SCHEMBL22945803 | 0.71 | PLG (0.41) | PLGPLAUUGT2B7MEN1KMT2A | |
| SCHEMBL2040052 | 0.71 | RECQL (0.44) | PLGPLAUUGT2B7TYK2MEN1 | |
| SCHEMBL15277731 | 0.71 | PLG (0.41) | PLGPLAUUGT2B7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516397-B1 | Amino-heteroaryl derivatives as HCN blockers | MERCK SHARP & DOHME (NL) | 2016-07-13 | — | — | EP | disclosed |
| EP-2516397-B1 | Amino-heteroaryl derivatives as HCN blockers | MERCK SHARP & DOHME (NL) | 2016-07-13 | — | — | EP | disclosed |
| US-8952001-B2 | Amino-heteroaryl derivatives as HCN blockers | MERCK SHARP & DOHME CORP. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952001-B2 | Amino-heteroaryl derivatives as HCN blockers | MERCK SHARP & DOHME CORP. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952001-B2 | Amino-heteroaryl derivatives as HCN blockers | MERCK SHARP & DOHME CORP. (US) | 2015-02-10 | — | — | US | disclosed |
| CN-102884048-B | Amino-heteroaryl derivatives as HCN blockers | MSD OSS BV | 2014-07-23 | — | — | CN | disclosed |
| CN-102884048-A | Amino-heteroaryl derivatives as HCN blockers | MSD OSS BV | 2013-01-16 | — | — | CN | disclosed |
| EP-2516397-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | MSD Oss B.V. (NL) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264728-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-10-18 | — | — | US | disclosed |
| US-20120264728-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-10-18 | — | — | US | disclosed |
| US-20120264728-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-10-18 | — | — | US | disclosed |
| WO-2011076723-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | N.V. ORGANON (NL) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264728-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | HCN1, HCN3, HCN2 | PLG 4717/4885PLAU 4816/4885UGT2B7 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.